A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Non-Commercial (NC): Only non-commercial uses of the work are permitted. No ...

Figure 1. Cardiovascular risk reduction in adults with type 2 diabetes: central illustration. GLP-1 indicates glucagon-like peptide 1; PCSK-9, proprotein convertase subtilisin/kexin type 9 serine ...

SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits on the evolution and progression of cardiomyopathy and nephropathy, which is characterized by a reduction in ...

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been proven to have cardiac and renal protective effects. The meta-analysis was performed to investigate whether SGLT2i can reduce the risk of ...

Coincidentally, Levels, a company she co-founded, sells a system that allows people to continuously track their blood glucose levels in real time. She claims this information can help people home ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are disease-modifying agents in type 2 diabetes mellitus (T2DM) and CKD, but studies on their use in cirrhosis are limited. We aimed to assess the ...